Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Essential Drug List To Be Released In Two Phases

This article was originally published in PharmAsia News

Executive Summary

According to authoritative sources, China will adopt a two-step approach for its national essential drug list release: a mini-list comprising 178 western medicines and 78 patent TCMs will be issued soon, while an enriched list is expected to come out after Aug. 16. China's Ministry of Health, National Development and Reform Commission and Ministry of Human Resources and Social Security have jointly discussed and confirmed the first batch of documents for healthcare reform, including the essential drug list, essential drug pricing, as well as tender and purchase specifics. Relevant administrations have selected Class I medical care institutions to pilot the mini-list. Another list may leave 5 percent of total medicines to local governments for selection and adjustment; however, the issue of dealing with specific drugs is still outstanding. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072040

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel